For Pet Insurance Partners

The Future of Pet Insurance Isn't Reactive. It's Proactive.

AnticiPet integrates genomic risk insights and advanced biomarker science into the core of insurance — shifting from reactive reimbursement to proactive, lifelong health protection.

Explore the partnership → How it works
Germline risk Drug response Early signals
100s
Diseases screened
1x
Sample, lifetime use
~50%
US homes with a dog
Whole genome sequencing
Early cancer detection
Organ failure signals
Key Benefits of Whole Genome Sequencing

One test. A lifetime of relevance.

Whole genome sequencing is performed once and surfaces health insights across the life of the dog — making it a uniquely powerful benefit for insurance policies.

Hereditary risk
100s
Of inherited disease risks flagged at onboarding — before symptoms ever appear.
Pharmacogenomics
Smarter Rx
Predicts how a dog will respond to common medications — guiding safer, more effective treatment.
Lifetime value
1×
Sample collected once. Insights re-surfaced at every relevant life stage — no resequencing needed.
Proactive care
Upstream
Enables prevention and early intervention — moving care ahead of expensive end-stage treatment.
For Pet Insurers

A genuine differentiator in a crowded market.

Pet insurance is at an inflection point: fast growing but undifferentiated. AnticiPet provides that difference — a science-backed benefit applicable for the life of the pet.

— 01

Stand out without pricing pressures

Pet parents benefit from genomic insights integrated into policies. Insurance providers benefit from reduced costs of care — a value exchange competitors aren't offering.

— 02

Lower long-term claims through earlier care

Genomic risk signals and early detection of organ failure or cancer enable preventative interventions — moving care upstream of the expensive end-stage treatments occurring today.

— 03

Deeper customer loyalty

Genomic information becomes more valuable as a pet ages. The benefit creates a lasting reason for policyholders to renew, year after year.

— 04

An ecosystem advantage

AnticiPet sits at the hub of insurance, nutrition, diagnostics, and veterinary care — coordinated benefits that compound in value for the policyholder.

— 05

Built on proven human-medicine foundations

We don't reinvent genomics. Hundreds of billions of dollars and decades of human research are now being applied in a veterinary context.

So, as responsible pet owners, we are willing to invest in these aspects of their care, often going above and beyond to ensure their well-being."
Arthur Salisbury · Founder, Pitbulls Home
Product Roadmap

A platform built for the life of the pet.

Genomic insights at onboarding. Biomarker testing through the senior years. Three complementary technologies, each addressing a different phase of the pet's life — and a different cost center for the insurer.

I
Phase I · Now

Whole genome sequencing for dogs

Insights into hundreds of inherited disease risks and responses to treatment — surfaced when it's relevant to age, breed, and health.

II
Phase II · Next

Early organ-failure detection

Testing for emergent liver and kidney disease — catching the conditions before they become acute.

III
Phase III · Horizon

Early cancer detection

Liquid biopsies are revolutionizing human oncology — now they can be brought to companion animals, enabling precision treatment when outcomes are best.

Leadership

Built by operators who've done this before.

AnticiPet's team combines decades of experience scaling diagnostics companies with deep scientific credentials in clinical genomics.

Katherine Varley

Katherine Varley, PhD

Co-Founder

Professor at the University of Utah Huntsman Cancer Institute. Develops molecular methods and bioinformatics to understand how gene regulation goes wrong in cancer — and to find biomarkers that improve treatment.

Research focus Clinical trial genomics · Epigenome engineering · Circulating tumor DNA · Metastasis drivers
Troy Moore

Troy Moore

Co-Founder

A longtime passion — backed by decades of experience — for building life-science companies from concept to operations. Focused on problem solving, development strategy, and revenue generation.

Selected experience Research Genetics · Open Biosystems · ThermoFisher · Kailos Genetics
Guido Baechler

Guido Baechler

Co-Founder

30+ years of global leadership across public and private life-science companies, with a track record of building and scaling diagnostics and biotech businesses from start-up through Nasdaq IPO.

Selected experience Mainz BioMed · Berkeley Life Science Advisors · SummerBio · Singulex · Roche Molecular Systems
Let's talk

Let's build a benefit unique to your policyholders.

We're partnering with a select group of forward-looking pet insurers to bring genomic medicine to their policyholders. If that sounds like you, we'd like to talk.

Start a partnership conversation →
Or email us directly at info@anticipet.bio